Other Posts
The American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 31 – June 4, 2019 in Chicago, IL. ASCO recently released their demographics for 2019 and we are going to compare the numbers from 2018.
The American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 31 – June 4, 2019 in Chicago, IL. ASCO recently released their demographics for 2019 and we are going to compare the numbers from 2018.
In 2019, there was a total of 42,500 attendees, a 4.4% increase from 2018 which had a total of 40,700 attendees. Out of the 42,500 attendees, 34,250 were professionals and 6,216 were exhibitors. The top countries in attendance in 2019 are the United States and China whereas in 2018, it was the US and Canada. This year, 55% of attendees were international while in 2018, 2% of guests were international. It’s clear that the numbers in 2019 have greatly increased since 2018 which is wonderful to see.
People attend the ASCO Annual Meeting every year and these increasing numbers show that more people have come together to meet each other, take in new information, and grow more within their skills and fields. Guests’ roles ranged from oncologists, pharmacists, biologists, researchers, and more.
Connecting with our clients is always a pleasure and these conferences give us the opportunity to say hello and touch base. We are always looking to attend conferences. Follow us on Twitter to stay up to date on our upcoming events or visit our website.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
